STAT+: FDA’s latest reorganization puts a new emphasis on its investigations
The FDA is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, according to three people familiar with the planning.
WASHINGTON — There’s about to be a new acronym in town.
The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.
That overhaul includes a new name: Meet the Office of Inspections and Investigations.
What's Your Reaction?
